What therapeutic areas does RISING focus on?

RISING focuses primarily on Cardiovascular and Neurology and 1 other therapeutic areas.

Data updated: May 24, 2026

RISING

Q: What drugs does RISING make?

RISING has 254 FDA-approved drugs including LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), SUMATRIPTAN AND NAPROXEN SODIUM, FENOFIBRIC ACID.

Generics

Cardiovascular Neurology Infectious Disease

RISING is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.

1958

Since

254

Drugs

Trials

New Drugs (2yr)

Modality:

4 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

Infectious Disease

Lower Respiratory Tract Infection

Approved 2013

SUMATRIPTAN AND NAPROXEN SODIUM

Migraine

Hypertriglyceridemia

PPAR alpha Approved 2013

CARBIDOPA, LEVODOPA AND ENTACAPONE

CNS

Approved 2012

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

ROCURONIUM BROMIDE NDA

2025-10-24

rocuronium bromide

Routine tracheal intubation

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

ROCURONIUM BROMIDE NDA

2025-06-09

rocuronium bromide

Routine tracheal intubation

PYRIDOSTIGMINE BROMIDE NDA

2024-10-04

pyridostigmine bromide

INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 34%

20 drugs

Neurology 22%

13 drugs

Infectious Disease 16%

9 drugs

Dermatology 16%

9 drugs

Oncology 12%

7 drugs